Does the media prefer ROIV or XENE?

In the previous week, Roivant Sciences had 3 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 9 mentions for Roivant Sciences and 6 mentions for Xenon Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.31 beat Xenon Pharmaceuticals' score of 1.11 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XENE or INSM?

In the previous week, Insmed had 12 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 18 mentions for Insmed and 6 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.11 beat Insmed's score of 0.93 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 11 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BNTX or XENE?

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than BioNTech. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 5 mentions for BioNTech. Xenon Pharmaceuticals' average media sentiment score of 1.11 beat BioNTech's score of 0.63 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XENE or GMAB?

In the previous week, Genmab A/S had 4 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 10 mentions for Genmab A/S and 6 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.11 beat Genmab A/S's score of 0.19 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Xenon Pharmaceuticals (XENE) Competitors

$66.04 -2.22 (-3.25%)

Closing price 04:00 PM Eastern

Extended Trading

$66.81 +0.77 (+1.16%)

As of 07:34 PM Eastern

Compare

XENE vs. ROIV, INSM, BNTX, VTRS, and GMAB

Should you buy Xenon Pharmaceuticals stock or one of its competitors? MarketBeat compares Xenon Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xenon Pharmaceuticals include Roivant Sciences (ROIV), Insmed (INSM), BioNTech (BNTX), Viatris (VTRS), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical products" industry.

How does Xenon Pharmaceuticals compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

In the previous week, Roivant Sciences had 3 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 9 mentions for Roivant Sciences and 6 mentions for Xenon Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.31 beat Xenon Pharmaceuticals' score of 1.11 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has higher revenue and earnings than Xenon Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,965.03	-$299.77M	-$0.60	N/A
Xenon Pharmaceuticals	$7.50M	851.21	-$345.91M	-$4.70	N/A

Roivant Sciences presently has a consensus price target of $33.59, suggesting a potential downside of 1.35%. Xenon Pharmaceuticals has a consensus price target of $77.20, suggesting a potential upside of 16.90%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Roivant Sciences has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Roivant Sciences beats Xenon Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Insmed?

Xenon Pharmaceuticals (NASDAQ:XENE) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Insmed had 12 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 18 mentions for Insmed and 6 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.11 beat Insmed's score of 0.93 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	11 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xenon Pharmaceuticals has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Xenon Pharmaceuticals' return on equity of -49.23% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Insmed	-144.44%	-130.11%	-51.57%

Xenon Pharmaceuticals has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	851.21	-$345.91M	-$4.70	N/A
Insmed	$606.42M	38.25	-$1.28B	-$5.75	N/A

Xenon Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Insmed has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Xenon Pharmaceuticals presently has a consensus price target of $77.20, suggesting a potential upside of 16.90%. Insmed has a consensus price target of $209.91, suggesting a potential upside of 96.14%. Given Insmed's higher probable upside, analysts clearly believe Insmed is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Insmed	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

Xenon Pharmaceuticals beats Insmed on 12 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than BioNTech. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 5 mentions for BioNTech. Xenon Pharmaceuticals' average media sentiment score of 1.11 beat BioNTech's score of 0.63 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xenon Pharmaceuticals has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

BioNTech presently has a consensus target price of $129.13, indicating a potential upside of 40.11%. Xenon Pharmaceuticals has a consensus target price of $77.20, indicating a potential upside of 16.90%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

BioNTech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Xenon Pharmaceuticals has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.18	-$1.29B	-$5.88	N/A
Xenon Pharmaceuticals	$7.50M	851.21	-$345.91M	-$4.70	N/A

Summary

Xenon Pharmaceuticals beats BioNTech on 10 of the 16 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Viatris?

Xenon Pharmaceuticals (NASDAQ:XENE) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Xenon Pharmaceuticals has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	851.21	-$345.91M	-$4.70	N/A
Viatris	$14.30B	1.38	-$3.51B	-$0.26	N/A

In the previous week, Xenon Pharmaceuticals had 6 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 0 mentions for Viatris. Xenon Pharmaceuticals' average media sentiment score of 1.11 beat Viatris' score of 0.00 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Xenon Pharmaceuticals	Positive
Viatris	Neutral

Xenon Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Viatris	-2.04%	19.04%	7.62%

Xenon Pharmaceuticals currently has a consensus target price of $77.20, suggesting a potential upside of 16.90%. Viatris has a consensus target price of $17.50, suggesting a potential upside of 3.00%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Xenon Pharmaceuticals has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Viatris has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Summary

Xenon Pharmaceuticals beats Viatris on 12 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Genmab A/S?

Xenon Pharmaceuticals (NASDAQ:XENE) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Xenon Pharmaceuticals presently has a consensus price target of $77.20, suggesting a potential upside of 16.90%. Genmab A/S has a consensus price target of $38.21, suggesting a potential upside of 36.92%. Given Genmab A/S's higher possible upside, analysts clearly believe Genmab A/S is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Genmab A/S had 4 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 10 mentions for Genmab A/S and 6 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.11 beat Genmab A/S's score of 0.19 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xenon Pharmaceuticals has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Genmab A/S has a net margin of 21.05% compared to Xenon Pharmaceuticals' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Genmab A/S	21.05%	15.34%	8.94%

Genmab A/S has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	851.21	-$345.91M	-$4.70	N/A
Genmab A/S	$3.72B	4.68	$963M	$1.32	21.14

Summary

Genmab A/S beats Xenon Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Xenon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XENE vs. The Competition

Export

Metric	Xenon Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.38B	$3.62B	$6.78B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.36%
P/E Ratio	-14.05	20.66	27.10	23.96
Price / Sales	851.21	300.74	573.91	112.12
Price / Cash	N/A	60.31	26.68	47.27
Price / Book	8.77	7.92	10.66	6.14
Net Income	-$345.91M	$23.81M	$3.60B	$331.74M
7 Day Performance	-2.48%	-1.27%	-1.51%	-1.72%
1 Month Performance	24.82%	2.56%	1.11%	-1.44%
1 Year Performance	109.05%	42.49%	23.77%	16.97%

Xenon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XENE Xenon Pharmaceuticals	2.8943 of 5 stars	$66.04 -3.3%	$77.20 +16.9%	+116.1%	$6.38B	$7.50M	N/A	210	News Coverage Positive News
ROIV Roivant Sciences	1.8665 of 5 stars	$34.51 -4.1%	$33.59 -2.7%	+201.7%	$25.87B	$8.26M	N/A	860
INSM Insmed	4.2154 of 5 stars	$109.14 -5.6%	$211.00 +93.3%	+5.6%	$25.06B	$606.42M	N/A	1,664	News Coverage Analyst Forecast
BNTX BioNTech	4.3424 of 5 stars	$90.07 -1.6%	$129.13 +43.4%	-16.9%	$23.14B	$3.25B	N/A	7,807	News Coverage Analyst Upgrade
VTRS Viatris	1.8937 of 5 stars	$16.39 +0.7%	$17.50 +6.8%	+94.7%	$18.95B	$14.30B	N/A	30,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XENE) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. ROIV, INSM, BNTX, VTRS, and GMAB

How does Xenon Pharmaceuticals compare to Roivant Sciences?

Summary

How does Xenon Pharmaceuticals compare to Insmed?

Summary

How does Xenon Pharmaceuticals compare to BioNTech?

Summary

How does Xenon Pharmaceuticals compare to Viatris?

Summary

How does Xenon Pharmaceuticals compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. ROIV, INSM, BNTX, VTRS, and GMAB

How does Xenon Pharmaceuticals compare to Roivant Sciences?

Is ROIV or XENE more profitable?

Does the media prefer ROIV or XENE?

Which has higher earnings & valuation, ROIV or XENE?

Do analysts rate ROIV or XENE?

Which has more volatility and risk, ROIV or XENE?

Do insiders and institutionals have more ownership in ROIV or XENE?

Summary

How does Xenon Pharmaceuticals compare to Insmed?

Do insiders & institutionals have more ownership in XENE or INSM?

Does the media refer more to XENE or INSM?

Is XENE or INSM more profitable?

Which has stronger earnings and valuation, XENE or INSM?

Which has more volatility and risk, XENE or INSM?

Do analysts recommend XENE or INSM?

Summary

How does Xenon Pharmaceuticals compare to BioNTech?

Does the media prefer BNTX or XENE?

Is BNTX or XENE more profitable?

Do analysts prefer BNTX or XENE?

Which has more volatility and risk, BNTX or XENE?

Do institutionals & insiders believe in BNTX or XENE?

Which has preferable valuation and earnings, BNTX or XENE?

Summary

How does Xenon Pharmaceuticals compare to Viatris?

Do insiders and institutionals hold more shares of XENE or VTRS?

Which has better earnings & valuation, XENE or VTRS?

Does the media favor XENE or VTRS?

Is XENE or VTRS more profitable?

Do analysts recommend XENE or VTRS?

Which has more volatility and risk, XENE or VTRS?

Summary

How does Xenon Pharmaceuticals compare to Genmab A/S?

Do institutionals and insiders hold more shares of XENE or GMAB?

Do analysts rate XENE or GMAB?

Does the media favor XENE or GMAB?

Which has more risk and volatility, XENE or GMAB?

Is XENE or GMAB more profitable?

Which has stronger earnings and valuation, XENE or GMAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools